Krsnaa Diagnostics Limited has informed the Exchange about Transcript
KRSNAA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Krsnaa Diagnostics hosted its Q4 FY '26 earnings call. FY '26 revenue stood at ~INR 7,728 million with EBITDA of ~INR 2,149 million (27.81% margin). PAT crossed INR 1,000 million for the first time at INR 1,014 million, with Q4 PAT of ~INR 417 million growing 101% YoY. The company operates 190+ CT/MRI centers, 147 pathology labs, and 4,700+ patient collection centers across 18 states. Retail contributed ~8% of revenues, scaling 6x from ~INR 10 crore in FY '25 to ~INR 60 crore in FY '26. Rajasthan PPP project, with ~INR 300 crore capex already largely deployed, is expected to start contributing revenue from Q1 FY '27 with a conservative full-year guidance of INR 100–150 crore. The company plans INR 500 crore total capex in FY '27 including Rajasthan and MRI expansion. DSO improved from 155 days to 139 days, with a target to reach sub-120 days in FY '27. The Board recommended a dividend of INR 2 per share.
Strong PAT growth and improving cash conversion are positives; however, muted revenue growth (only ~1% YoY in FY '26 vs ~16% in FY '25) reflects delays in project ramp-ups and non-renewals. Investors should monitor Rajasthan execution and new PPP order pipeline for near-term growth visibility.